Mature response data from a phase 2 study of PI3K-delta inhibitor idelalisib in patients with double (rituximab and alkylating agent)-refractory indolent B-cell non-Hodgkin lymphoma (iNHL)

A. Davies; A. K. Gopal; B. S. Kahl; S. de Vos; N. D. Wagner-Johnston; S. J. Schuster; W. J. Jurczak; I. W. Flinn; C. R. Flowers; R. Dansey; P. Martin; A. Viardot; K. A. Blum; A. H. Goy; J. Gribben; H-T Arkenau; R. Johnson; K. Linton; P. L. Zinzani; M. Dreyling; G. A. Salles

Mature response data from a phase 2 study of PI3K-delta inhibitor idelalisib in patients with double (rituximab and alkylating agent)-refractory indolent B-cell non-Hodgkin lymphoma (iNHL)

A. Davies, A. K. Gopal, B. S. Kahl, S. de Vos, N. D. Wagner-Johnston, S. J. Schuster, W. J. Jurczak, I. W. Flinn, C. R. Flowers, R. Dansey, P. Martin, A. Viardot, K. A. Blum, A. H. Goy, J. Gribben, H-T Arkenau, R. Johnson, K. Linton, P. L. Zinzani, M. DreylingG. A. Salles

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	Undefined
Pages (from-to)	2-2
Number of pages	1
Journal	British Journal of Haematology
Volume	165
Issue number	1
Publication status	Published - 2014

Cite this

Davies, A., Gopal, A. K., Kahl, B. S., de Vos, S., Wagner-Johnston, N. D., Schuster, S. J., Jurczak, W. J., Flinn, I. W., Flowers, C. R., Dansey, R., Martin, P., Viardot, A., Blum, K. A., Goy, A. H., Gribben, J., Arkenau, H-T., Johnson, R., Linton, K., Zinzani, P. L., ... Salles, G. A. (2014). Mature response data from a phase 2 study of PI3K-delta inhibitor idelalisib in patients with double (rituximab and alkylating agent)-refractory indolent B-cell non-Hodgkin lymphoma (iNHL). British Journal of Haematology, 165(1), 2-2.

@article{95ffe2cf3ebc4fe9b437c15fbb4dce01,

title = "Mature response data from a phase 2 study of PI3K-delta inhibitor idelalisib in patients with double (rituximab and alkylating agent)-refractory indolent B-cell non-Hodgkin lymphoma (iNHL)",

author = "A. Davies and Gopal, {A. K.} and Kahl, {B. S.} and {de Vos}, S. and Wagner-Johnston, {N. D.} and Schuster, {S. J.} and Jurczak, {W. J.} and Flinn, {I. W.} and Flowers, {C. R.} and R. Dansey and P. Martin and A. Viardot and Blum, {K. A.} and Goy, {A. H.} and J. Gribben and H-T Arkenau and R. Johnson and K. Linton and Zinzani, {P. L.} and M. Dreyling and Salles, {G. A.}",

year = "2014",

language = "Undefined",

volume = "165",

pages = "2--2",

journal = "British Jounal Haematology",

issn = "0007-1048",

publisher = "John Wiley & Sons Ltd",

number = "1",

}

Davies, A, Gopal, AK, Kahl, BS, de Vos, S, Wagner-Johnston, ND, Schuster, SJ, Jurczak, WJ, Flinn, IW, Flowers, CR, Dansey, R, Martin, P, Viardot, A, Blum, KA, Goy, AH, Gribben, J, Arkenau, H-T, Johnson, R , Linton, K, Zinzani, PL, Dreyling, M & Salles, GA 2014, 'Mature response data from a phase 2 study of PI3K-delta inhibitor idelalisib in patients with double (rituximab and alkylating agent)-refractory indolent B-cell non-Hodgkin lymphoma (iNHL)', British Journal of Haematology, vol. 165, no. 1, pp. 2-2.

Mature response data from a phase 2 study of PI3K-delta inhibitor idelalisib in patients with double (rituximab and alkylating agent)-refractory indolent B-cell non-Hodgkin lymphoma (iNHL). / Davies, A.; Gopal, A. K.; Kahl, B. S. et al.

In: British Journal of Haematology, Vol. 165, No. 1, 2014, p. 2-2.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - Mature response data from a phase 2 study of PI3K-delta inhibitor idelalisib in patients with double (rituximab and alkylating agent)-refractory indolent B-cell non-Hodgkin lymphoma (iNHL)

AU - Davies, A.

AU - Gopal, A. K.

AU - Kahl, B. S.

AU - de Vos, S.

AU - Wagner-Johnston, N. D.

AU - Schuster, S. J.

AU - Jurczak, W. J.

AU - Flinn, I. W.

AU - Flowers, C. R.

AU - Dansey, R.

AU - Martin, P.

AU - Viardot, A.

AU - Blum, K. A.

AU - Goy, A. H.

AU - Gribben, J.

AU - Arkenau, H-T

AU - Johnson, R.

AU - Linton, K.

AU - Zinzani, P. L.

AU - Dreyling, M.

AU - Salles, G. A.

PY - 2014

Y1 - 2014

UR - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000334923300004&KeyUID=WOS:000334923300004

M3 - Meeting Abstract

VL - 165

SP - 2

EP - 2

JO - British Jounal Haematology

JF - British Jounal Haematology

SN - 0007-1048

IS - 1

ER -

Mature response data from a phase 2 study of PI3K-delta inhibitor idelalisib in patients with double (rituximab and alkylating agent)-refractory indolent B-cell non-Hodgkin lymphoma (iNHL)

Other files and links

Cite this